Beroni Group Limited (BNIGF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Beroni Group Limited (BNIGF) with AI Score 48/100 (Weak). Beroni Group Limited operates in the industrials sector, focusing on diverse products like smoking control aids, air purifiers, and health supplements. Market cap: 0, Sector: Industrials.
Last analyzed: Mar 17, 2026Beroni Group Limited (BNIGF) Industrial Operations Profile
Beroni Group Limited, based in Australia, develops and distributes a range of health-related products, including smoking cessation aids, air purifiers, and diagnostic kits, primarily targeting markets in China, Australia, the United States, and Japan. The company operates in a competitive landscape within the broader industrials sector.
Investment Thesis
Beroni Group Limited presents a speculative investment opportunity, given its presence in diverse sectors such as health supplements, air purification, and diagnostics. The company's gross margin of 58.1% indicates potential profitability, but its negative P/E ratio of -0.02 and a significantly negative profit margin of -2982.3% raise concerns about its financial stability. Growth catalysts include expansion of its diagnostic kit sales and potential breakthroughs in its drug development programs. However, investors should be wary of the risks associated with OTC-listed companies, including limited liquidity and disclosure requirements. The company's beta of 0.89 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 58.1% indicates potential for profitability in product sales.
- Operates in multiple segments including Nicobloc, Fogibloc Air Purifier, and Viral Diagnostic Kits.
- Geographic reach includes China, Australia, the United States, and Japan.
- Involved in research and development of new drugs and cell therapies.
- Market Capitalization of $0.00B indicates a micro-cap company with associated risks and opportunities.
Competitors & Peers
Strengths
- Diversified product portfolio.
- Presence in multiple geographic markets.
- Focus on health and environmental products.
- Ongoing research and development efforts.
Weaknesses
- Negative profit margin.
- Limited financial resources compared to larger competitors.
- Reliance on OTC market listing.
- Unknown disclosure status.
Catalysts
- Ongoing: Expansion of distribution network for existing product lines.
- Upcoming: Potential regulatory approvals for new diagnostic kits.
- Ongoing: Progress in clinical trials for new drug candidates.
- Upcoming: Launch of new e-commerce platform for healthcare products.
Risks
- Ongoing: Intense competition in the health and environmental product markets.
- Potential: Regulatory changes affecting product approvals and sales.
- Potential: Economic downturns impacting consumer spending.
- Ongoing: Risks associated with OTC market listing, including limited liquidity and disclosure.
Growth Opportunities
- Expansion of Viral Diagnostic Kits: The global market for diagnostic kits is expected to grow significantly, driven by increased awareness of infectious diseases and the need for rapid and accurate testing. Beroni Group's SARS-CoV-2 IgG/IgM antibody detection kit and CII-ArboViroPlex rRT-PCR assay position it to capitalize on this trend. Successful commercialization and distribution of these kits could drive revenue growth in the short to medium term.
- Development of New Anti-Cancer Drugs: Beroni Group's research and development efforts in new anti-cancer drugs represent a long-term growth opportunity. The global oncology market is substantial and growing, with significant unmet needs. While drug development is a high-risk endeavor, successful development and approval of a novel anti-cancer drug could generate substantial returns for the company over the long term.
- E-commerce Platform for Pharmaceutical and Healthcare Products: Launching and scaling an e-commerce platform for pharmaceutical and healthcare products could provide Beroni Group with a direct-to-consumer channel and expand its market reach. The e-commerce market for healthcare products is growing rapidly, driven by convenience and accessibility. A successful platform could increase sales and improve customer engagement.
- Stem Cell Cosmetic Products: The market for stem cell cosmetic products is expanding, driven by consumer interest in anti-aging and regenerative skincare solutions. Beroni Group's stem cell cosmetic products could appeal to this growing market segment. Effective marketing and distribution of these products could contribute to revenue growth.
- Geographic Expansion: Beroni Group currently operates in China, Australia, the United States, and Japan. Expanding into new geographic markets, particularly in Asia and Europe, could provide additional growth opportunities. Successful market entry and penetration would require careful planning and execution, but could significantly increase the company's customer base and revenue.
Opportunities
- Expansion of diagnostic kit sales.
- Development of new anti-cancer drugs.
- Growth in e-commerce for healthcare products.
- Geographic expansion into new markets.
Threats
- Intense competition in the health and environmental product markets.
- Regulatory changes affecting product approvals and sales.
- Economic downturns impacting consumer spending.
- Risks associated with OTC market listing.
Competitive Advantages
- Proprietary formulations for products like NicoBloc.
- Established distribution channels in key markets.
- Ongoing research and development efforts.
- Diversified product portfolio across multiple segments.
About BNIGF
Founded in 2014 and headquartered in Sydney, Australia, Beroni Group Limited operates as a diversified industrial company with a focus on health and environmental products. The company's initial focus was on developing and marketing NicoBloc, a smoking cessation product designed to reduce the harmful effects of smoking. Over time, Beroni Group expanded its product portfolio to include Fogibloc air purifiers, Olansi water filters, and a variety of health supplements and cosmetic products. The company operates through multiple segments, including Nicobloc, Fogibloc Air Purifier, Olansi Water Filter, Health Supplements, Cosmetic products, and Viral Diagnostic Kits. Beroni Group has also ventured into the development and sale of diagnostic kits, including those for detecting SARS-CoV-2 and other viruses. Furthermore, the company is involved in research and development of new drugs, gene detection, and cell therapies for cancer and anti-aging treatments. Beroni Group distributes its products across China, Australia, the United States, and Japan, utilizing both online and offline channels.
What They Do
- Develops and sells smoking control products like NicoBloc.
- Offers air purification systems under the Fogibloc brand.
- Provides water filters through the Olansi brand.
- Markets health care products and supplements.
- Sells cosmetic products, including rejuvenation liquids and silk masks.
- Offers SARS-CoV-2 IgG/IgM antibody detection kits.
- Engages in research and development of new drugs and clinical trials.
- Develops cell therapies for cancer and anti-aging treatments.
Business Model
- Develops and manufactures health and environmental products.
- Sells products through online and offline channels in multiple countries.
- Generates revenue from product sales and diagnostic services.
- Invests in research and development to create new products and therapies.
Industry Context
Beroni Group operates within the industrials sector, specifically in the conglomerates industry, which includes companies with diverse business operations. The global health and wellness market is experiencing growth, driven by increasing consumer awareness and demand for preventative healthcare products. The air purifier market is also expanding due to rising concerns about air quality, particularly in urban areas. Beroni Group competes with companies like CIRX, CSLI, DLOC, DSUS, and ELGL, which may have greater resources and market share. The company's success depends on its ability to differentiate its products and effectively penetrate its target markets.
Key Customers
- Individuals seeking smoking cessation aids.
- Consumers concerned about air and water quality.
- Individuals interested in health supplements and cosmetic products.
- Healthcare providers and laboratories using diagnostic kits.
- Patients seeking cell therapies for cancer and anti-aging treatments.
Financials
Chart & Info
Beroni Group Limited (BNIGF) stock price: Price data unavailable
Latest News
No recent news available for BNIGF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BNIGF.
Price Targets
Wall Street price target analysis for BNIGF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BNIGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry ConglomeratesLeadership: Boqing Zhang
CEO
Boqing Zhang is the CEO of Beroni Group Limited. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background cannot be provided at this time. Further research would be required to ascertain his qualifications and experience prior to joining Beroni Group.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Boqing Zhang's achievements and strategic decisions as CEO of Beroni Group Limited. Further research would be needed to assess the company's performance and milestones under his leadership.
BNIGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Beroni Group Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Higher risk of fraud or mismanagement.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the company's management team.
- Understand the risks associated with OTC trading.
- Consult with a qualified financial advisor.
- Monitor news and developments related to the company.
- Company has been in operation since 2014.
- Operates in multiple geographic markets.
- Offers a range of products and services.
- Engages in research and development activities.
BNIGF Industrials Stock FAQ
What does Beroni Group Limited do?
Beroni Group Limited is an industrial company that develops, manufactures, and sells a diverse range of products, including smoking control aids (NicoBloc), air purifiers (Fogibloc), water filters (Olansi), health supplements, cosmetic products, and viral diagnostic kits. The company operates through multiple segments, serving markets in China, Australia, the United States, and Japan. Beroni Group also engages in research and development of new drugs and cell therapies, aiming to expand its product offerings and address unmet needs in the healthcare sector.
What do analysts say about BNIGF stock?
As of March 17, 2026, there is no available analyst coverage or consensus on Beroni Group Limited (BNIGF). The company's OTC listing and limited financial disclosure may contribute to the lack of analyst coverage. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio and earnings per share, should be interpreted with caution due to the company's negative profitability.
What are the main risks for BNIGF?
Beroni Group Limited faces several risks, including intense competition in the health and environmental product markets, potential regulatory changes affecting product approvals and sales, and economic downturns impacting consumer spending. As an OTC-listed company, BNIGF is subject to risks associated with limited liquidity, disclosure, and regulatory oversight. The company's negative profit margin and reliance on product sales also pose financial risks. Investors should carefully consider these risks before investing in BNIGF.
What are the key factors to evaluate for BNIGF?
Beroni Group Limited (BNIGF) currently holds an AI score of 48/100, indicating low score. Key strength: Diversified product portfolio.. Primary risk to monitor: Ongoing: Intense competition in the health and environmental product markets.. This is not financial advice.
How frequently does BNIGF data refresh on this page?
BNIGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BNIGF's recent stock price performance?
Recent price movement in Beroni Group Limited (BNIGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BNIGF overvalued or undervalued right now?
Determining whether Beroni Group Limited (BNIGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BNIGF?
Before investing in Beroni Group Limited (BNIGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited.
- OTC market data may be less reliable than major exchange data.